Dr. Reddy's Laboratories Limited (DRREDDY): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Dr. Reddy's Laboratories Limited, explained in plain English.
- Dr. Reddy's Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- DRREDDY closed at ₹1,398.20 on 18 November 2026.
- Over the past year the shares are up 12.4%, trading between ₹1,101.00 and ₹1,414.90.
- Reported fundamentals show return on equity of 7.34%, a net margin of 8.48%, debt to equity of 18.57.
- Our Pulse grade checklist scores it F (30/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 24.23% with a maximum drawdown of -17.45% and a beta of 0.44 against NIFTY 50.
- Recent coverage: Stocks to watch: ITC, Lupin, NBCC, SBI, Dr Reddy's, Bosch, Ola Electric
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 18 Nov 2026. Market opens at 9:15 IST.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited (DRREDDY)
₹1,388
▲ 10.1 (+0.73%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Neutral momentum · 3/51M
+12.57%
3M
+16.44%
6M
+3.84%
1Y
+11.54%
Where it sits in its 52-week range
100%Below 52-week high
0.0%
22.2% above the low
Momentum read
Neutral
3/5 checks passed
52-wk high
₹1,388
52-wk low
₹1,135.6
Market cap
₹1,15,713 Cr
P/E (trailing)
41.3
Dividend yield
—
ROE
7.34%
Profit margin
8.48%
Revenue growth
-1.5%
Price / Book
2.99
Debt / Equity
18.57
EPS (TTM)
33.59
Book value
₹463.56
Beta
0.44
Pulse grade: F, 30 out of 100
Momentum
B- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✕RSI in healthy 45-70 zone
- ✓Positive 3-month return
Growth
F- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✕Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
F- ✕Return on equity above Pharma & Healthcare median (14.64%)
- ✕Return on equity above 12%
- ✕Profit margin above Pharma & Healthcare median (13.82%)
Safety
D- ✕Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹8,671 crore · net profit ₹925 crore · margin 10.7%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
| Peer | Price ₹ | Day change | From 52-wk high |
|---|---|---|---|
| SUNPHARMA | 1,870 | +0.13% | -6.55% |
| CIPLA | 1,388 | -0.47% | -9.61% |
| DIVISLAB | 11,150 | +0.63% | -3.59% |
| APOLLOHOSP | 8,712.5 | -0.67% | -3.93% |
| LUPIN | 1,950 | -1.35% | -22.46% |
| AUROPHARMA | 1,794.1 | +0.01% | -3.30% |
DRREDDY headlines
No DRREDDY stories right now.
DRREDDY filings & announcements
DRREDDY, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
24.22%
Sharpe ratio
0.3
Sortino ratio
0.49
Max drawdown
-17.45%
Daily VaR (95%)
-1.98%
CAGR (1Y)
11.21%
Return skew
1.28
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.